Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 19/20 | 0.66 |
| ▸ | BCR | P11274 | 18/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752653 | 0.87 | MEN1 (0.56) | ABL1BCRMAPK1TRPV1 | |
| SCHEMBL5753112 | 0.85 | TRPV1 (0.52) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL5753334 | 0.82 | TRPV1 (0.56) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL17487030 | 0.82 | ABL1 (0.76) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL5753921 | 0.81 | TRPV1 (0.57) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL5923900 | 0.81 | TRPV1 (0.65) | ABL1BCRMAPTMAPK1TRPV1 | |
| SCHEMBL3450466 | 0.80 | ABL1 (0.79) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL22440745 | 0.80 | ABL1 (0.76) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3900043 | 0.80 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL10013582 | 0.78 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651619-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMIN ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009977-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMINA ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-20060229308-A1 | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands | NEUROGEN CORPORATION (US) | 2006-10-12 | — | — | US | disclosed |
| EP-1651619-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMIN ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009977-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMINA ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229308-A1 | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands | TRPV1, GPR17, TRPV2 | ABL1 3315/4885BCR 1838/4885KDM4E 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.